nach oben

Inflammation

Erschienen in:

01.02.2012

Sphingosine-1-Phosphate Attenuates Lung Injury Induced by Intestinal Ischemia/Reperfusion in Mice: Role of Inducible Nitric-Oxide Synthase

verfasst von: Renyu Ding, Jiali Han, Yu Tian, Renxuan Guo, Xiaochun Ma

Erschienen in: Inflammation | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Multiple organ failure, including acute lung injury (ALI), is a common complication of intestinal ischemia/reperfusion (I/R) injuries and contributes to its high mortality rate. Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid that enhances vascular barrier function and has anti-inflammatory effects. In the current study, we investigated the effect of S1P on lung injury induced by intestinal I/R. Mice were randomly assigned to one of the following groups: (1) sham-operated mice, (2) mice exposed to superior mesenteric artery occlusion for 45 min followed by reperfusion for 6 h, or (3) mice exposed to I/R that received S1P (100 μg/kg, administered by peritoneal injection). S1P markedly attenuated lung injury, manifested by the improvement of histological changes and significant decreases of lung water content. Moreover, S1P markedly reduced MDA levels and MPO activity in the lung tissues, and plasma levels of proinflammatory cytokines. In addition, S1P treatment significantly suppressed NO generation accompanied by down-regulation of iNOS expression. The results indicate that S1P has a protective effect on lung injury induced by I/R, which may be related to its suppression of iNOS-induced NO generation. S1P seems to be an effective therapeutic agent for intestinal I/R-related lung injury.

Homer-Vanniasinkam, S., J.N. Crinnion, and M.J. Gough. 1997. Post-ischaemic organ dysfunction: a review. Eur. J. Vasc. Endovasc. Surg. 14: 195–203.PubMedCrossRef

Matthay, M.A., G.A. Zimmerman, C. Esmon, J. Bhattacharya, B. Coller, C.M. Doerschuk, J. Floros, Gimbrone MA Jr., E. Hoffman, R.D. Hubmayr, M. Leppert, S. Matalon, R. Munford, P. Parsons, A.S. Slutsky, K.J. Tracey, P. Ward, D.B. Gail, and A.L. Harabin. 2003. Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. Am. J. Respir. Crit. Care Med. 167: 1027–1035.PubMedCrossRef

Scott, J.A., and D.G. McCormack. 1999. Nonadrenergic noncholinergic vasodilation of guinea pig pulmonary arteries is mediated by nitric oxide. Can. J. Physiol. Pharmacol. 77: 89–95.PubMedCrossRef

Scott, J.A., I. Craig, and D.G. McCormack. 1996. Nonadrenergic noncholinergic relaxation of human pulmonary arteries is partially mediated by nitric oxide. Am. J. Respir. Crit. Care Med. 154: 629–632.PubMed

Ermert, M., C. Ruppert, A. Günther, H.R. Duncker, W. Seeger, and L. Ermert. 2002. Cell-specific nitric oxide synthase-isoenzyme expression and regulation in response to endotoxin in intact rat lungs. Lab. Invest. 82: 425–441.PubMedCrossRef

Robbins, R.A., D.R. Springall, J.B. Warren, O.J. Kwon, L.D. Buttery, A.J. Wilson, I.M. Adcock, V. Riveros-Moreno, S. Moncada, J. Polak, and P.J. Barnes. 1994. Inducible nitric oxide synthase is increased in murine lung epithelial cells by cytokine stimulation. Biochem. Biophys. Res. Commun. 198: 835–843.PubMedCrossRef

Nakayama, D.K., D.A. Geller, C.J. Lowenstein, H.D. Chern, P. Davies, B.R. Pitt, R.L. Simmons, and T.R. Billiar. 1992. Cytokines and lipopolysaccharide induce nitric oxide synthase in cultured rat pulmonary artery smooth muscle. Am. J. Respir. Cell Mol. Biol. 7: 471–476.PubMed

Rosen, H., and E.J. Goetzl. 2005. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol. 5: 560–570.PubMedCrossRef

Anliker, B., and J. Chun. 2004. Cell surface receptors in lysophospholipid signaling. Semin. Cell Dev. Biol. 15: 457–465.PubMedCrossRef

10.

Hla, T. 2004. Physiological and pathological actions of sphingosine 1-phosphate. Semin. Cell Dev. Biol. 15: 513–520.PubMedCrossRef

11.

Peng, X., P.M. Hassoun, S. Sammani, B.J. McVerry, M.J. Burne, H. Rabb, D. Pearse, R.M. Tuder, and J.G. Garcia. 2004. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am. J. Respir. Crit. Care Med. 169: 1245–1251.PubMedCrossRef

12.

Dantas, A.P., J. Igarashi, and T. Michel. 2003. Sphingosine 1-phosphate and control of vascular tone. Am. J. Physiol. Heart Circ. Physiol. 284: H2045–H2052.PubMed

13.

Hughes, J.E., S. Srinivasan, K.R. Lynch, R.L. Proia, P. Ferdek, and C.C. Hedrick. 2008. Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ. Res. 102: 950–958.PubMedCrossRef

14.

Machida, T., Y. Hamaya, Izumi, Y. Hamaya, K. Iizuka, Y. Igarashi, M. Minami, R. Levi, and M. Hirafuji. 2008. Sphingosine 1-phosphate inhibits nitric oxide production induced by interleukin-1beta in rat vascular smooth muscle cells. J. Pharmacol. Exp. Ther. 325: 200–209.PubMedCrossRef

15.

Lane, J.S., K.E. Todd, M.P. Lewis, B. Gloor, S.W. Ashley, H.A. Reber, D.W. McFadden, and C.F. Chandler. 1997. Interleukin-10 reduces the systemic inflammatory response in a murine model of intestinal ischemia/reperfusion. Surgery 122: 288–294.PubMedCrossRef

16.

Matute-Bello, G., R.K. Winn, M. Jonas, E.Y. Chi, T.R. Martin, and W.C. Liles. 2001. Fas (CD95) induces alveolar epithelial cell apoptosis in vivo: implications for acute pulmonary inflammation. Am. J. Pathol. 158: 153–161.PubMedCrossRef

17.

Suzuki, K., H. Ota, S. Sasagawa, T. Sakatani, and T. Fujikura. 1983. Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Anal. Biochem. 132: 345–352.PubMedCrossRef

18.

Giakoustidis, A.E., D.E. Giakoustidis, S. Iliadis, G. Papageorgiou, K. Koliakou, N. Kontos, I. Taitzoglou, E. Botsoglou, V. Papanikolaou, K. Atmatzidis, D. Takoudas, and A. Antoniadis. 2006. Attenuation of intestinal ischemia/reperfusion induced liver and lung injury by intraperitoneal administration of (−)-epigallocatechin-3-gallate. Free Radic. Res. 40: 103–110.PubMedCrossRef

19.

Ohkawa, H., N. Ohishi, and K. Yagi. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95: 351–358.PubMedCrossRef

20.

Sud, N., S.M. Wells, S. Sharma, D.A. Wiseman, J. Wilham, and S.M. Black. 2008. Asymmetric dimethylarginine inhibits HSP90 activity in pulmonary arterial endothelial cells: role of mitochondrial dysfunction. Am. J. Physiol. Cell Physiol. 294: C1407–C1418.PubMedCrossRef

21.

Turnage, R.H., K.S. Guice, and K.T. Oldham. 1994. Endotoxemia and remote organ injury following intestinal reperfusion. J. Surg. Res. 56: 571–578.PubMedCrossRef

22.

Olanders, K., Z. Sun, A. Börjesson, M. Dib, E. Andersson, A. Lasson, T. Ohlsson, and R. Andersson. 2002. The effect of intestinal ischemia and reperfusion injury on ICAM-1 expression, endothelial barrier function, neutrophil tissue influx, and protease inhibitor levels in rats. Shock 18: 86–92.PubMedCrossRef

23.

Ishii, H., M. Ishibashi, M. Takayama, T. Nishida, and M. Yoshida. 2000. The role of cytokine-induced neutrophil chemoattractant-1 in neutrophil-mediated remote lung injury after intestinal ischaemia/reperfusion in rats. Respirology 5: 325–331.PubMed

24.

Garcia, J.G., F. Liu, A.D. Verin, A. Birukova, M.A. Dechert, W.T. Gerthoffer, J.R. Bamberg, and D. English. 2001. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J. Clin. Invest. 108: 689–701.PubMed

25.

Whetzel, A.M., D.T. Bolick, S. Srinivasan, T.L. Macdonald, M.A. Morris, K. Ley, and C.C. Hedrick. 2006. Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ. Res. 99: 731–739.PubMedCrossRef

26.

Kimura, T., H. Tomura, C. Mogi, A. Kuwabara, A. Damirin, T. Ishizuka, A. Sekiguchi, M. Ishiwara, D.S. Im, K. Sato, M. Murakami, and F. Okajima. 2006. Role of scavenger receptor class b type i and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J. Biol. Chem. 281: 37457–37467.PubMedCrossRef

27.

Bolick, D.T., S. Srinivasan, K.W. Kim, M.E. Hatley, J.J. Clemens, A. Whetzel, N. Ferger, T.L. Macdonald, M.D. Davis, P.S. Tsao, K.R. Lynch, and C.C. Hedrick. 2005. Sphingosine-1-phosphate prevents tumor necrosis factor-{alpha}-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler. Thromb. Vasc. Biol. 25: 976–981.PubMedCrossRef

28.

Tölle, M., A. Pawlak, M. Schuchardt, A. Kawamura, U.J. Tietge, S. Lorkowski, P. Keul, G. Assmann, J. Chun, B. Levkau, M. van der Giet, and J.R. Nofer. 2008. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase dependent monocyte chemoattractant protein-1 production. Arterioscler. Thromb. Vasc. Biol. 28: 1542–1548.PubMedCrossRef

29.

McVerry, B.J., X.Q. Peng, P.M. Hassoun, S. Sammani, B.A. Simon, and J.G. Garcia. 2004. Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am. J. Respir. Crit. Care Med. 170: 987–993.PubMedCrossRef

30.

Schaphorst, K.L., E. Chiang, K.N. Jacobs, A. Zaiman, V. Natarajan, F. Wigley, and J.G. Garcia. 2003. Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products. Am. J. Physiol. Lung Cell. Mol. Physiol. 285: L258–L267.PubMed

31.

Liu, H.B., N.Q. Cui, Q. Wang, D.H. Li, and X.P. Xue. 2008. Sphingosine-1-phosphate and its analogue FTY720 diminish acute pulmonary injury in rats with acute necrotizing pancreatitis. Pancreas 36: e10–e15.PubMedCrossRef

32.

Park, S.W., M. Kim, S.W. Chen, V.D. D’Agati, and H.T. Lee. 2010. Sphinganine-1-phosphate attenuates both hepatic and renal injury induced by hepatic ischemia and reperfusion in mice. Shock 33: 31–42.PubMedCrossRef

33.

Park, S.W., M. Kim, S.W. Chen, K.M. Brown, V.D. D’Agati, and H.T. Lee. 2010. Sphinganine-1-phosphate protects kidney and liver after hepatic ischemia and reperfusion in mice through S1P1 receptor activation. Lab. Invest. 90: 1209–1224.PubMedCrossRef

34.

Szabó, C., A.L. Salzman, and H. Ischiropoulos. 1995. Endotoxin triggers the expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in the rat aorta in vivo. FEBS Lett. 363: 235–238.PubMedCrossRef

35.

Minc-Golomb, D., I. Tsarfaty, and J.P. Schwartz. 1994. Expression of inducible nitric oxide synthase by neurones following exposure to endotoxin and cytokine. Br. J. Pharmacol. 112: 720–722.PubMed

36.

Lu, J.L., L.M. Schmiege 3rd, L. Kuo, and J.C. Liao. 1996. Downregulation of endothelial constitutive nitric oxide synthase expression by lipopolysaccharide. Biochem. Biophys. Res. Commun. 225: 1–5.PubMedCrossRef

37.

Chatterjee, A., C. Snead, G. Yetik-Anacak, G. Antonova, J. Zeng, and J.D. Catravas JD. 2008. Heat shock protein 90 inhibitors attenuate LPS-induced endothelial hyperpermeability. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L755–L763.PubMedCrossRef

38.

Farley, K.S., L.F. Wang, H.M. Razavi, C. Law, M. Rohan, D.G. McCormack, and S. Mehta. 2006. Effects of macrophage inducible nitric oxide synthase in murine septic lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 290: L1164–L1172.PubMedCrossRef

39.

Razavi, H.M., F. Wangle, S. Weicker, M. Rohan, C. Law, D.G. McCormack, and S. Mehta. 2004. Pulmonary neutrophil infiltration in murine sepsis: role of inducible nitric oxide synthase. Am. J. Respir. Crit. Care Med. 170: 227–233.PubMedCrossRef

40.

Scumpia, P.O., P.J. Sarcia, V.G. DeMarco, B.R. Stevens, and J.W. Skimming. 2002. Hypothermia attenuates iNOS, CAT-1, CAT-2, and nitric oxide expression in lungs of endotoxemic rats. Am. J. Physiol. Lung Cell. Mol. Physiol. 283: L1231–L1238.PubMed

41.

Okamoto, I., M. Abe, K. Shibata, N. Shimizu, N. Sakata, T. Katsuragi, and K. Tanaka. 2000. Evaluating the role of inducible nitric oxide synthase using a novel and selective inducible nitric oxide synthase inhibitor in septic lung injury produced by cecal ligation and puncture. Am. J. Respir. Crit. Care Med. 162: 716–722.PubMed

42.

Pryor, W.A., and G.L. Squadrito. 1995. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am. J. Physiol. 268: L699–L722.PubMed

43.

Gocan, N.C., J.A. Scott, and K. Tyml. 2000. Nitric oxide produced via neuronal NOS may impair vasodilatation in septic rat skeletal muscle. Am. J. Physiol. Heart Circ. Physiol. 278: H1480–H1489.PubMed

44.

Enkhbaatar, P., K. Murakami, K. Shimoda, A. Mizutani, R. McGuire, F. Schmalstieg, R. Cox, H. Hawkins, J. Jodoin, S. Lee, L. Traber, D. Herndon, and D. Traber. 2003. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole attenuates acute lung injury in an ovine model. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285: R366–R372.PubMed

45.

Xin, C., S. Ren, B. Kleuser, S. Shabahang, W. Eberhardt, H. Radeke, M. Schäfer-Korting, J. Pfeilschifter, and A. Huwiler. 2004. Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-beta-induced cell responses. J. Biol. Chem. 279: 35255–35262.PubMedCrossRef

46.

Eckle, T., A. Grenz, S. Laucher, and H.K. Eltzschig. 2008. A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J. Clin. Invest. 118: 3301–3315.PubMed

Titel: Sphingosine-1-Phosphate Attenuates Lung Injury Induced by Intestinal Ischemia/Reperfusion in Mice: Role of Inducible Nitric-Oxide Synthase
verfasst von: Renyu Ding
Jiali Han
Yu Tian
Renxuan Guo
Xiaochun Ma
Publikationsdatum: 01.02.2012
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 1/2012
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-011-9301-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Sphingosine-1-Phosphate Attenuates Lung Injury Induced by Intestinal Ischemia/Reperfusion in Mice: Role of Inducible Nitric-Oxide Synthase

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Subacute Inflammatory Activation in Subjects with Acute Coronary Syndrome and Left Ventricular Dysfunction

Impact of Selenium on the Leukotriene B4 Synthesis Pathway during Isoproterenol-Induced Myocardial Infarction in Experimental Rats

Interaction of Serine Proteases from Polymorphonuclear Leucocytes with the Cell Surface and Heparin

Inhibitory Effects of Prior Low-dose X-irradiation on Cold-induced Brain Injury in Mouse

Stimulation of FasL Induces Production of Proinflammatory Mediators Through Activation of Mitogen-Activated Protein Kinases and Nuclear Factor-κB in THP-1 Cells

Genistein Inhibit Cytokines or Growth Factor-Induced Proliferation and Transformation Phenotype in Fibroblast-Like Synoviocytes of Rheumatoid Arthritis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin